Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis commences Pallas trial for Multaq

Sanofi-aventis commences Pallas trial for Multaq

13th May 2010

Sanofi-aventis has initiated a potentially groundbreaking new clinical trial which will assess the safety and efficacy of its heart disease treatment Multaq.

The phase IIIb Pallas trial will begin enrolling patients in the third quarter of 2010 and is to involve a total of 10,800 people across 43 countries.

Its objective is to determine the potential clinical benefits of Multaq in reducing major adverse cardiovascular events among sufferers of permanent atrial fibrillation (AF).

Trial investigator Dr Stuart Connolly said that no anti-arrhythmic drug has been able to demonstrate significant morbidity and mortality reductions in a large-scale trial of this kind before.

Dr Marc Cluzel, executive vice-president of research and development at Sanofi-aventis, added: “The initiation of the Pallas trial confirms our strong belief in Multaq and our commitment to improve AF patient wellbeing and overall cardiovascular health.”

Earlier this month, Sanofi-aventis announced a new collaboration with Glenmark Pharmaceuticals which will aim to develop treatments for conditions such as diabetic neuropathic pain and osteoarthritic pain.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.